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A concise route to the 6-azido-6-deoxy-α-galactosyl-
phytosphingosine derivative 9 is reported.  Orthogonal 
protection of the two amino groups allows elaboration of 9 
into a range of 6-N-derivatized α-galactosyl ceramides by 
late-stage introduction of the acyl chain of the ceramide 
and the 6-N-group in the sugar head-group. Biologically 
active glycolipids 6 and 8 have been synthesized to 
illustrate the applicability of the approach.  
 
The synthetic glycolipid α-galactosyl ceramide (α-GalCer),1 
also known as KRN7000 (1) (Figure 1), has been shown to 
bind to the protein CD1d.  Recognition of the resulting 
glycolipid-protein complex by T cell receptors (TCRs) located 
on the surface of invariant natural killer T (iNKT) cells, leads 
to activation of the immune response through the release of a 
diverse range of cytokines, including both Th1 (IFNγ) and Th2 
(IL-4) cytokines.2-4 The release of Th1 cytokines may 
contribute to antitumour and antimicrobial functions, while the 
release of Th2 cytokines is believed to play a role in 
alleviating autoimmune diseases5-7 such as multiple sclerosis8 
and arthritis.9  When both Th1 and Th2 cytokines are released 
together, their effects oppose one another, which may induce 
mixed and unpredictable biological effects.10 This is the case 
upon α-GalCer/CD1d activation of the immune response, 
which has complicated efforts to develop KRN7000 as a 
therapeutic agent. The search for analogues of this glycolipid, 
which induce a more biased Th1/Th2 response, is therefore a 
current focus of many immunological studies. 
A number of α-GalCer analogues have been reported that 
exhibit more skewed Th1/Th2 cytokine profiles compared 
with that elicited by α-GalCer 1 (Figure 1).11 Truncation of the 
acyl12 (2) and sphingosine8,13 (OCH (3)) chains, and the 
incorporation of unsaturation in the acyl chain (α-GalCer 
C20:2 (4))14 result in CD1d agonists that generate a more Th2-
biased  response.  Examples of more Th1-biasing molecules 
are much rarer;15,16a the C-glycosyl analogue of KRN7000, α-
C-GalCer (5) is one such molecule that has been shown to 
induce a useful Th1-biased response.15 
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            n = 13, X = O
5   R = (CH2)24CH3, n = 13, X = CH2  
Figure 1. Prototypical KRN7000 (1) and biologically active 
analogues 2, 3, 4 and 5.  
 
There has been recent interest in galactosyl ceramides in 
which the hydroxyl group at the 6-position of the sugar head 
group has been modified (Figure 2).16 Crystal structures of the 
CD1d-KRN7000 complex17 and a TCR-KRN7000-CD1d 
complex18 show that the 6-hydroxyl group is not involved 
directly in hydrogen bonding with either the CD1d protein or 
the TCR.  Moreover, it has been shown that the TCR-
glycolipid-CD1d interaction can tolerate derivatization at 
C6.16d,19 Savage has reported that GalCer 6 (PBS-57) offers 
improved solubility over KRN7000, effectively stains both 
mouse and human NKT cells, and stimulates cytokine release 
at low concentrations.16b Wang has synthesized the 
biotinylated α-GalCer analogue 7 to facilitate detection of this 
antigen in flow cytometry assays.16c  In this study, the 
problematic low solubility of these α-GalCer analogues was 
remedied by incorporating a truncated acyl chain. Of 
particular interest, Van Calenbergh recently found that 
substituting the 6-hydroxyl group of 1 for a range of aryl 
ureas, such as 8, induced a more Th1-biased cytokine response 
than is observed with α-GalCer.16a 
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Figure 2. Biologically active 6-derivatized α-galactosyl ceramides 6-
8 and our target precursor 9.  
 
 
1  
Previously reported routes to 6-derivatized α-GalCer 
analogues are somewhat lengthy, involve extensive protecting 
group manipulation, and often suffer from poor overall yields. 
In addition, they do not allow the late-stage variation of the 
acyl chain; a change of acyl chain therefore requires a 
complete repeat of the synthetic sequence.  Here we present a 
concise synthesis of the orthogonally protected diamino α-
GalCer analogue 9 (Figure 2), which is primed for further 
elaboration to 6-N-derivatized galactosyl ceramides. The 
described route allows both the acyl chain of the ceramide unit 
and the 6-substituent of the sugar head group to be varied at a 
late stage of the synthesis, thus providing access to a 
potentially large and varied library of this class of compound.  
 
The retrosynthesis of our target 9 is shown in Figure 3. With 
careful choice of protecting groups, it was envisaged that 9 (or 
the potentially more useful Boc-deprotected derivative 10) 
could be accessed in a single step from fully-protected azide 
11, which in turn could be accessed from alcohol 12, using a 
Mitsunobu reaction to install the azide. At this point we would 
require a selective mono-deprotection of the primary 6-OH for 
which there was precedent from Fernández who showed that 
1,2,3,4-tetra-O-trimethylsilylgalactose could be obtained by 
treating 1,2,3,4,6-penta-O-trimethylsilyl-galactose 13 with 
acetic acid.20 We therefore reasoned that alcohol 12 could be 
accessed from 14 in a similar manner.  Glycoside 14 was 
further disconnected to glycosyl donor 15 and sphingosine 
ceptor 16. ac  
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Figure 3. Retrosynthetic analysis of targets 9 and 10.  
 
Trimethylsilyl groups were chosen as the protecting groups for 
the sugar unit owing to 1) their ease of attachment to the 
galactose starting material;20,23 2) the ability to mono-deprotect 
the primary silyl ether selectively;20 3) the ease with which the 
remaining silyl groups can be removed when required; and 4) 
the ‘arming’ effect that silyl groups impart on the sugar donor 
in glycosylation reactions.21 tert-Butyldimethylsilyl (TBDMS) 
groups were chosen as the protecting groups for the 
sphingosine acceptor.  While conferring an increased level of 
stability during the synthesis, as well as providing an extra 
handle for 1H- and 13C NMR spectroscopic analysis, we 
envisaged these bulkier silyl groups could also be removed 
along with the trimethylsilyl groups of the sugar head unit in a 
single step. 
 
Per-TMS-protected galactose 13 was synthesized in 
quantitative yield by treating D-galactose with 
chlorotrimethylsilane and hexamethyldisilazane in the 
presence of pyridine.22 Acceptor 16 was accessed in three 
steps from commercially available phytosphingosine 17 
(Scheme 1):  Boc protection afforded carbamate 18, which 
underwent threefold silylation of the triol functionality to 
provide silyl ether 19.  Selective mono-deprotection of the 
primary silyl ether in 19 with HF-pyridine23 concluded the 
ynthesis of glycosyl acceptor 16.  s 
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cheme 1. Synthesis of glycosyl acceptor 16. 
The key step in the synthesis of 9 employed Gervay-Hague’s 
elegant glycosylation methodology in which the glycosyl 
iodide donor 15 was generated in situ by treating per-TMS-
protected galactose 13 with iodotrimethylsilane.24 Glycosyl 
iodide 15 reacted with acceptor 16 in the presence of Bu4NI 
and Hünig’s base, to provide glycoside 20 exclusively as the 
α-anomer in 80% yield, thus providing a short and scalable 
route to galactosyl ceramide precursors (Scheme 2). With this 
method of glycosylation, the protecting groups are usually 
removed immediately via an acidic work-up.24 However, it 
was desirable in our case to leave the silyl protecting groups in 
the product intact and effect a selective mono-deprotection of 
the primary trimethylsilyl group instead. To this end, 
following Fernández’s method for 6-trimethylsilyl ether 
deprotection,20 treatment of 20 with acetic acid in 
acetone/methanol gave mono-deprotected 21 in a satisfactory 
78% yield, and provided the valuable handle for modifying the 
6-position.  Alcohol 21 was converted in 92% yield to azide 
22 by a Mitsunobu reaction employing diphenylphosphoryl 
azide (DPPA), diisopropyl azodicarboxylate (DIAD) and 
triphenylphosphine.25 Treating azide 22 with 
tetrabutylammonium fluoride (TBAF) successfully removed 
the five silyl protecting groups; however the residual 
tetrabutylammonium by-products could not be separated from 
the polar product by flash column chromatography. While the 
use of silica-supported TBAF ameliorated this problem, a 
better deprotection method involved stirring 22 with 10% 
trifluoroacetic acid (TFA) in dichloromethane overnight. 
Interestingly, while this method produced pentaol 9 
exclusively, treatment of azide 22 with neat TFA for 10 
minutes resulted in clean conversion to Boc-deprotected amine 
10 (Scheme 2). 
 
To illustrate the versatility of amine 10 we completed the 
synthesis of two biologically active 6-derivatized 〈-galactosyl 
 
2  
ceramides 6 (PBS-57) and 8, which differ in both the acyl 
chain of the ceramide base and the nitrogen-containing 
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Scheme 2. Synthesis of α-galactosides 9 and 10.  
 
functionality at the 6-position of the sugar head group 
(Scheme 3). Treating a biphasic mixture of amine 10 in THF / 
8 M aqueous NaOAc with nervonoyl chloride afforded 6-
azido GalCer 23 in 81% yield. Subsequent Staudinger24d,26 
reaction followed by treatment with acetyl chloride afforded 
PBS-57 (6).16b Alternatively, acylation of 10 using 
hexacosanoyl chloride, to provide amide 24, followed by 
Staudinger reduction24d,26 and then treatment with 
phenylisocyanate, afforded Th1-biasing α-GalCer derivative 
.16a 8
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Scheme 3. Synthesis of α-galactosyl ceramides 6 and 8. 
An even more convergent route to our target molecules would 
employ 6-azido galactose 25 in the key glycosylation step 
(Scheme 4). Azide 25 was synthesized by deprotecting the 
primary silyl ether in per-TMS-protected galactose 13 to 
afford alcohol 26, followed by Mitsunobu reaction with 
DPPA, DIAD and PPh3.  Following the same procedure as 
with per-TMS-protected galactose 13, 6-azido galactose 25 
was treated with TMSI and the resulting glycosyl iodide 27 
added to a solution of acceptor 16, Bu4NI and Hünig’s base in 
dichloromethane. Unfortunately, this reaction was 
unsuccessful, only providing various TMS-deprotection 
products of 6-azido galactose 25. The failure of this sugar 
donor to undergo glycosylation can be understood by the 
electron-withdrawing nature of the azide group imparting a 
strongly deactivating effect.27 Acceptors such as alcohol 16 
already display attenuated nucleophilicity owing to the 
presence of a hydrogen bond between the alcohol oxygen 
atom and the carbamate hydrogen atom,28 and while the 
reaction of 16 proceeds readily with ‘armed’ per-TMS donor 
15, the corresponding less-armed per-benzylated glycosyl 
iodide is unreactive to this class of acceptor.24a,b These 
observations serve to highlight how sensitive is the reactivity 
of these glycosyl iodide donors to small changes in the sugar 
substitution pattern. 
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S cheme 4.  Attempted more convergent synthesis of α-galactoside 22.  
In summary, a short and convenient route to 6-N-derivatized 
galactosyl ceramides has been developed, which allows late-
stage variation of both the N-acyl chain of the sphingosine unit 
and the substituent introduced at the 6-position of the sugar.  
Azides 23 and 24 are also primed for further functionalization 
via Click Chemistry.  Future work will focus on using such 
derivatization strategies in the synthesis and biological 
evaluation of novel 6-N-derivatized glycolipids. 
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xperimental Section 
General Procedure for Selective 6-Desilylation (Alcohols 
21 and 26). AcOH (3.00 mmol) was added to a solution of 
galactoside 20 or 13 (1.57 mmol) in acetone (3.5 mL) and 
MeOH (4.7 mL) at 0 °C.  The reaction mixture was allowed to 
warm to rt. After 8 h, the reaction was quenched by the 
addition of NaHCO3 (5.95 mmol) and then filtered. After 
concentration of the filtrate under reduced pressure, the 
resulting oil was purified by flash column chromatography 
(EtOAc in hexane) to afford alcohol 21 (from 20) or 26 (from 
3) as a colorless oil.  1
 
 
3  
General Procedure for Mitsunobu Reaction (Azides 22 and 
25). PPh3 (1.86 mmol), DIAD (1.86 mmol) and DPPA (1.86 
mmol) were added sequentially to a cooled solution of alcohol 
21 or 26 (0.90 mmol) in THF (20 mL). The mixture was 
allowed to warm to rt. and then stirred overnight. 
Concentration under reduced pressure followed by purification 
of the residue by flash column chromatography (EtOAc in 
hexane) afforded azide 22 (from 21) or 25 (from 26) as a 
colorless oil. 
 
Pentaol 9. TFA (0.50 mL, 6.6 mmol) was added dropwise 
over 5 min to a solution of azide 22 (200 mg, 0.19 mmol) in 
CH2Cl2 (5 mL) at rt.  After 30 min, the reaction mixture was 
concentrated under reduced pressure to afford pentaol 9 as a 
colorless oil (115 mg, quant.): [〈]20D +12.4 (c 0.5, 
CDCl3:CD3OD, 2:1); ⎨max(film)/cm−1 3282s br (O−H), 2114s 
(N3), 1696m (C=O); ™H(300 MHz, CDCl3:CD3OD, 2:1) 0.85 
(t, J 6.0, 3H), 1.18-1.39 (stack, 22H), 1.40-1.71 (stack, 4H), 
1.44 (s, 9H), 3.26 (A of ABX, JA-B 12.6, JA-X 4.9, 1H), 3.51-
3.64 (stack, 3H), 3.65-3.98 (stack, 7H), 4.89 (d, J 3.3, 1H); 
™C(100 MHz, CDCl3:CD3OD, 2:1) 14.3 (CH3), 23.2 (CH2), 
26.4 (CH2), 28.6 (CH3), [29.9, 30.2, 32.4, 32.8 (CH2, 
resonance overlap)], 51.7 (CH), 51.8 (CH2), 68.3 (CH2), 69.3 
(CH), 70.4 (CH), 70.6 (2 × CH, resonance overlap), 72.5 
(CH), 75.3 (CH), 80.1 (C), 156.8 (C); MS (TOF ES+) m/z 
627.3 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
29H56N4O9Na [M + Na]+ 627.3945, found 627.3956. C 
Amine 10 from azide 22: TFA (1.0 mL, 13.2 mmol) was 
added dropwise over 5 min to azide 22 (400 mg, 0.38 mmol) 
at rt. After 30 min, the reaction mixture was concentrated 
under reduced pressure. The resulting colorless oil was used in 
the next step without further purification (192 mg, quant.). 
From azide 9: TFA (0.50 mL, 6.6 mmol) was added dropwise 
over 5 min to azide 9 (114 mg, 0.19 mmol) at rt. After 30 min, 
the reaction mixture was concentrated under reduced pressure. 
The resulting colorless oil was used in the next step without 
further purification (96 mg, quant.). 
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